New hope for Tough-to-Treat leukemia: early trial of ABBV-453 underway
NCT ID NCT06291220
First seen Jan 11, 2026 · Last updated May 04, 2026 · Updated 15 times
Summary
This early-phase study tests an experimental drug called ABBV-453 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments. Participants first receive a standard antibody (obinutuzumab) to reduce tumor burden, then take increasing doses of ABBV-453 pills to find the safest and most effective dose. The study monitors side effects, drug levels in the blood, and how well the disease responds over about 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health /ID# 265136
Charlotte, North Carolina, 28204-2963, United States
-
Austin Health /ID# 256776
Heidelberg, Victoria, 3084, Australia
-
Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 263062
Perugia, 06156, Italy
-
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 263433
Berlin, 12203, Germany
-
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 267158
Irvine, California, 92618, United States
-
City of Hope /ID# 253904
Duarte, California, 91010, United States
-
Duplicate_Duke Cancer Center /ID# 258707
Durham, North Carolina, 27710-3000, United States
-
Gold coast University Hospital /ID# 255785
Southport, Queensland, 4215, Australia
-
Hadassah Medical Center-Hebrew University /ID# 254721
Jerusalem, Jerusalem, 91120, Israel
-
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 263065
Bologna, 40138, Italy
-
IRCCS Ospedale San Raffaele /ID# 263064
Milan, Milano, 20132, Italy
-
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 264622
Billings, Montana, 59102, United States
-
MD Anderson Cancer Center /ID# 253713
Houston, Texas, 77030, United States
-
Royal Perth Hospital /ID# 256464
Perth, Western Australia, 6000, Australia
-
Royal Prince Alfred Hospital /ID# 263129
Sydney, New South Wales, 2050, Australia
-
The Chaim Sheba Medical Center /ID# 254383
Ramat Gan, Tel Aviv, 5265601, Israel
-
Universitaetsklinikum Halle (Saale) /ID# 263299
Halle, Saxony-Anhalt, 06120, Germany
-
Universitaetsklinikum Hamburg-Eppendorf /ID# 263730
Hamburg, 20246, Germany
-
Universitaetsklinikum Schleswig-Holstein - Campus Kiel /ID# 263150
Kiel, Schleswig-Holstein, 24105, Germany
-
Universitaetsklinikum Ulm /ID# 263148
Ulm, Baden-Wurttemberg, 89081, Germany
-
Yitzhak Shamir Medical Center /ID# 257626
Ẕerifin, Central District, 70300, Israel
Conditions
Explore the condition pages connected to this study.